CA-NOODLE.AI
16.1.2020 15:02:14 CET | Business Wire | Press release
Leading Enterprise Artificial Intelligence® provider Noodle.ai and the digitalization team at SMS group , a trailblazer in digitalization for plant and equipment used in steel and nonferrous-metals production and processing, launched MPV today. MPV is the first joint AI-driven application for the steel industry. The launch follows the announcement of their partnership in June 2019.
As steel industry margins continue to shrink, one promising way for manufacturers to increase profitability is to pursue more advanced, high-strength steel production for applications such as automotive and electrical. However, production of these advanced steel grades requires much tighter control of the overall production process, which is impacted by numerous parameters across the mill.
The MPV (Mechanical Properties Variability) application utilizes artificial intelligence and machine learning to create a unique 'sense, predict, and recommend' framework that addresses challenges associated with the variability of mechanical properties in steel production. Mechanical properties include things such as yield strength, tensile strength, and elongation. The application senses patterns within mill data to fully understand the drivers of mechanical property variability. It then predicts when increased variability will occur and recommends the optimal input parameters, or PDI settings, required to optimize target mechanical properties such as yield strength, tensile strength, and elongation. As a result, the MPV application can help steel manufacturers achieve cost savings 3 ways: by reducing mechanical properties variability, reducing alloy costs due to better variability control, and minimizing out-of-spec production, which are sold as secondary grades or scrapped. One steel manufacturer using MPV is anticipating savings $2M per year.
“Our ability to deploy AI to produce steel with tighter tolerances allows us to address the requirements of high margin segments such as automotive and electrical, which immediately impacts our top line revenues in addition to the obvious cost savings,” said Denis Hennessy, Director of Product Development at Big River Steel, after implementing the MPV application.
In addition to addressing these challenges in mechanical properties variability, the AI and machine learning solutions that Noodle.ai and SMS digital have co-developed will also help steel manufacturers optimize product quality, asset availability and production efficiency. Together, Noodle.ai and SMS digital combine manufacturing equipment expertise, process modeling experience, and cutting-edge data science to accelerate time to value, enabling customers to quickly realize bottom-line impact.
“This partnership with SMS digital was created to make efficiency improvements that not only help steel manufacturers’ bottom line, but to rid the world of unnecessary industrial waste that often plagues this industry,” said Stephen Pratt, Founder and CEO, Noodle.ai. “We are encouraged by the results we’ve already seen with this application developed in partnership with SMS digital, and anticipate being able to assist an even larger list of steel manufacturers as we enter 2020 with MPV and the other applications we develop together.”
About Noodle.ai
Noodle.ai applies advanced data science to industries at the core of the global economy to create a world without waste. With Noodle.ai’s advanced Enterprise AI® applications, business leaders are empowered to make better decisions, reduce wasted energy, money, and resources, and ensure their businesses are built to last. Noodle.ai focuses on radical efficiency for supply chain and manufacturing using leading-edge artificial intelligence.
About SMS digital comprising SMS group Inc. Digital Solutions and SMS digital GmbH
SMS digital GmbH, the digital subsidiary of SMS group GmbH, and SMS group Inc. Digital Solutions collectively are a market leading supplier of digitalization for plant and equipment used in steel and NF-metals production and processing. SMS group GmbH generates worldwide sales totaling EUR 3.3 billion with more than 14,000 employees.
In close collaboration with its customers, SMS digital identifies and develops innovative products for the metals industry building on most advanced development techniques, in-depth metallurgical process knowhow and technological expert knowledge. SMS digital helps its customers make their plants and machines ready for the digital age by means of digital applications and the use of AI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom